Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03610581 |
|
Recruitment Status :
Terminated
(Low enrolment and increasing COVID restrictions, following an earlier enrolment pause in April made it clear that completion of the study would not be feasible)
First Posted : August 1, 2018
Last Update Posted : December 17, 2020
|
Sponsor:
Janssen Vaccines & Prevention B.V.
Collaborator:
Bavarian Nordic
Information provided by (Responsible Party):
Janssen Vaccines & Prevention B.V.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The main purpose of this study is to assess safety and reactogenicity of the 3 vaccine regimens.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Human Papillomavirus Infections | Biological: Ad26.HPV16 Biological: Ad26.HPV18 Biological: MVA.HPV16/18 Biological: Placebo | Phase 1 Phase 2 |
This study is part of a vaccine program which aims to generate a therapeutic vaccine for women with HPV types 16 or 18 infection, with a focus on early disease interception. The study consists of 3 periods: Screening period of up to 42 days (6 weeks), followed by prime and boost immunizations and follow-up visits up to 12 months after the first vaccination. Evaluation of the safety/reactogenicity of the vaccine regimens will include physical assessment by study-site personnel, participant reports on signs and symptoms and laboratory assessments following vaccinations. Immunogenicity and Virology/Histology assessments will also be performed.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 9 participants |
| Allocation: | Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-blind, Placebo-controlled, First-in-Human, Phase 1/2a Study to Evaluate Safety, Reactogenicity and Immunogenicity of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine Components and an MVA-vectored HPV16/18 Vaccine Component in Otherwise Healthy Women With HPV16 or 18 Infection of the Cervix |
| Actual Study Start Date : | September 27, 2018 |
| Actual Primary Completion Date : | October 15, 2020 |
| Actual Study Completion Date : | October 15, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Regimen 1: Single Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18
Participants will receive a dose of adenovirus serotype 26 (Ad26)-human papillomavirus (HPV)16 or HPV18 (Ad26.HPV16 or Ad26.HPV18) as prime immunization and a dose of Modified Vaccinia Ankara (MVA)-HPV16/18 (MVA.HPV16/18) as boost immunization.
|
Biological: Ad26.HPV16
Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
Other Name: JNJ-63682918 Biological: Ad26.HPV18 Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
Other Name: JNJ-63682931 Biological: MVA.HPV16/18 Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
Other Name: JNJ-65195208 |
|
Experimental: Regimen 2: Double Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18
Participants will receive a double dose of Ad26.HPV16 or Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
|
Biological: Ad26.HPV16
Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
Other Name: JNJ-63682918 Biological: Ad26.HPV18 Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
Other Name: JNJ-63682931 Biological: MVA.HPV16/18 Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
Other Name: JNJ-65195208 |
|
Experimental: Regimen 3: Ad26.HPV16/Ad26.HPV18 mix and MVA.HPV16/18
Participants will receive a mix of Ad26.HPV16/Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
|
Biological: Ad26.HPV16
Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
Other Name: JNJ-63682918 Biological: Ad26.HPV18 Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
Other Name: JNJ-63682931 Biological: MVA.HPV16/18 Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
Other Name: JNJ-65195208 |
|
Placebo Comparator: Control: Placebo
Participants will receive matched placebo as prime and boost immunizations.
|
Biological: Placebo
Participants will receive matched placebo as a solution for intramuscular injection. |
Primary Outcome Measures :
- Percentage of Participants with Solicited Local and Systemic Adverse Events (AEs) [ Time Frame: 7 Days after each vaccination (approximately up to Day 64) ]Solicited local AEs: pain/tenderness, erythema, and induration/swelling. Solicited systemic AEs: headache, fatigue, myalgia, arthralgia, chills and fever.
- Percentage of Participants with Unsolicited AEs [ Time Frame: 28 Days after each vaccination (approximately up to Day 85) ]Unsolicited AEs will include all AEs for which the participant is not specifically questioned in the participant diary.
- Percentage of Participants with Serious Adverse Events (SAEs) [ Time Frame: Approximately up to Month 12 ]SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
Secondary Outcome Measures :
- Percentage of Participants with Human Papillomavirus (HPV)-Specific CD4+ and CD8+ T-Cell Responses [ Time Frame: 21 Days after last vaccination (approximately Day 78) ]Expression of cytokines (for example [e.g.] interferon gamma [IFNγ], tumor necrosis factor alpha [TNFα], interleukin [IL]-2) by CD4+ and CD8+ T cell subsets will be determined by flow cytometry.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Willing and able to adhere to the prohibitions and restrictions specified in this protocol
- Must have an human papillomavirus (HPV) type 16 or 18 infection of the cervix as determined by a qualitative PCR test within 8 weeks prior to screening or at the time of screening. Available history of high-risk (HR)-HPV positivity and HPV16 or HPV18 positivity positivity will be recorded
- Must have a recent colposcopy result (with a maximum of 12 months old at screening); in case a colposcopy has not been performed before, it will be done as screening procedure
- Contraceptive (birth control) use by participants should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies
- Agrees not to donate blood until 3 months after receiving the last dose of study vaccine
Exclusion Criteria:
- In case cytology results are available, participant has current or history of high-grade squamous intraepithelial lesion (HSIL), adenocarcinoma in situ (AIS) or any high-grade vulvar, vaginal or anal intraepithelial neoplasia
- Current or history of cervical intraepithelial neoplasia (CIN)2+ or cervical cancer
- Confirmed co-infection with both HPV16 and HPV18
- History of an underlying clinically significant acute or chronic medical condition, other than infection with HPV, or physical examination findings for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
- Tests positive for human immunodeficiency virus (HIV) at screening
- Chronic active hepatitis B or hepatitis C infection, verified at screening by hepatitis B surface antigen or anti-hepatitis C virus antibody, respectively
- Vaginal atrophy with or without topical hormonal therapies or systemic selective estrogen receptor modulators
- Exposed to at least 1 dose of an HPV prophylactic vaccine or participant has participated in the past in another preventive or therapeutic HPV vaccine study
- Clinically significant gynecological abnormalities that could, in the judgment of the investigator, interfere with study evaluation (for example [e.g.], prolapse, myoma, fibroid, hysterectomy)
- Symptomatic vaginal or genital infection (including genital herpes) as confirmed by physician or investigator
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03610581
Locations
| United States, Florida | |
| Doral Medical Research | |
| Doral, Florida, United States, 33166 | |
| Clinical Physiology Associates | |
| Fort Myers, Florida, United States, 33912 | |
| San Marcus Research Clinic, Inc. | |
| Miami Lakes, Florida, United States, 33014 | |
| Florida Research Center Inc. | |
| Miami, Florida, United States, 33174 | |
| United States, Iowa | |
| University of Iowa Hospital | |
| Iowa City, Iowa, United States, 52242 | |
| United States, Kansas | |
| University of Kansas Medical Center | |
| Kansas City, Kansas, United States, 66160 | |
| Heartland Research Associates, LLC | |
| Newton, Kansas, United States, 67114 | |
| United States, Louisiana | |
| Medpharmics, LLC | |
| Metairie, Louisiana, United States, 70006 | |
| United States, Nebraska | |
| Meridian Clinical Research, LLC | |
| Norfolk, Nebraska, United States, 68701 | |
| United States, New York | |
| Columbia University Medical Center | |
| New York, New York, United States, 10032 | |
| United States, Tennessee | |
| VGR & NOCCR - Knoxville | |
| Knoxville, Tennessee, United States, 37920 | |
| Belgium | |
| UZ Leuven | |
| Leuven, Belgium, 3000 | |
Sponsors and Collaborators
Janssen Vaccines & Prevention B.V.
Bavarian Nordic
Investigators
| Study Director: | Janssen Vaccines & Prevention B.V. Clinical Trial | Janssen Vaccines & Prevention B.V. |
| Responsible Party: | Janssen Vaccines & Prevention B.V. |
| ClinicalTrials.gov Identifier: | NCT03610581 |
| Other Study ID Numbers: |
CR108458 2018-000200-41 ( EudraCT Number ) VAC81623HPV1002 ( Other Identifier: Janssen Vaccines & Prevention B.V. ) |
| First Posted: | August 1, 2018 Key Record Dates |
| Last Update Posted: | December 17, 2020 |
| Last Verified: | December 2020 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Infection Communicable Diseases Papillomavirus Infections |
DNA Virus Infections Virus Diseases Tumor Virus Infections |